<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564951</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-02/MG-01</org_study_id>
    <nct_id>NCT03564951</nct_id>
  </id_info>
  <brief_title>Ablation of Anisochronous Zones vs Spatio-temporal Dispersal Zones With Antral Electrical Isolation During Radiofrequency Treatment of Paroxysmal or Persistent Atrial Fibrillation</brief_title>
  <acronym>ISOCHRONE-AF</acronym>
  <official_title>Comparison of Ablation of Anisochronous Zones vs Spatio-temporal Dispersal Zones in Addition to Antral Electrical Isolation During Radiofrequency Treatment of Paroxysmal or Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using isochronous maps during radiofrequency ablation procedures may identify the driver
      zones responsible for atrial fibrillation maintenance with greater accuracy compared to a
      conventional procedure (simple antral isolation of the associated pulmonary veins or, if
      necessary, combined with removal of spatio-temporal dispersal zones) that do not use
      isochronous maps, and thus improve the efficiency and safety of atrial fibrillation treatment
      by radiofrequency treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation relapse between groups</measure>
    <time_frame>Month 18</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation relapse between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia occurrence between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>Arrhythmia, including atrial tachycardia detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia occurrence between groups</measure>
    <time_frame>Month 18</time_frame>
    <description>Arrhythmia, including atrial tachycardia detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of isochrone and voltage maps</measure>
    <time_frame>Day 0</time_frame>
    <description>Binary yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum variation of conduction speed between variation healthy zones with anisochronic zones in the same anatomic region</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the decreasing velocities between healthy zones and anisochronic zones in the same anatomic region</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of wave front rotation between healthy zones and anisochronic zones in the same anatomic region</measure>
    <time_frame>Day 0</time_frame>
    <description>degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of radiofrequency between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of lesion volume between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Force-time integral, lesion size index or stroke volume index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treated zones between groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of treated zones between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>List locations most frequently treated</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of each</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without relapse of the subgroups paroxysmal versus persistent atrial fibrillation.</measure>
    <time_frame>Month 18</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without relapse of the subgroups treated using the Carto- vs Rhythmia-guided ablation approaches.</measure>
    <time_frame>Month 18</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ablation of Atrial fibrillation using spatio-temporal dispersion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isochrone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablation of concordance zones using isochrone and voltage maps</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation</intervention_name>
    <description>ablation of Atrial fibrillation using spatio-temporal dispersion</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation</intervention_name>
    <description>ablation of concordance zones using isochrone and voltage maps</description>
    <arm_group_label>Isochrone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  The patient has paroxysmal or persistent atrial fibrillation

          -  The patient is available for 18 month follow-up

        Exclusion Criteria:

          -  The subject is participating in a category 1 interventional study, or is in a period
             of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The patient is pregnant or breastfeeding

          -  Sinus rhythm has not been able to be determined using external electric cardioversion

          -  Patient not susceptible to atrial fibrillation following wide antrum circle ablation

          -  The subject has already been included in the study (patients cannot be included more
             than once)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Granier, MD</last_name>
      <phone>04.67.33.67.33</phone>
      <email>m-granier@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Granier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Massin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc Pasquie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-François Winum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

